What are the considerations for an adult patient with a history of migraines and possibly other pain or inflammatory conditions when taking meloxicam (nonsteroidal anti-inflammatory drug (NSAID)) and rizatriptan (triptan) together?

Meloxicam and Rizatriptan Combination Therapy

The combination of meloxicam (an NSAID) with rizatriptan (a triptan) is explicitly recommended by current guidelines as first-line therapy for moderate to severe migraine attacks, and this combination is safe and more effective than either agent alone. 1

Evidence-Based Rationale for Combination Therapy

• The American College of Physicians (2025) specifically recommends adding a triptan to an NSAID for patients who do not achieve sufficient pain relief with an NSAID alone, making this combination a guideline-endorsed standard of care for moderate to severe episodic migraine. 1

• Combination therapy (triptan + NSAID) provides superior efficacy compared to either agent alone, with 130 more patients per 1000 achieving sustained pain relief at 48 hours and 90 more patients per 1000 achieving pain relief at 2 hours. 2

• Research evidence supports this combination specifically with rizatriptan: An open-label pilot study demonstrated that combining rizatriptan with an NSAID (rofecoxib, a COX-2 inhibitor similar in mechanism to meloxicam) reduced headache recurrence rates from 53% to 20% (p<0.001) and increased sustained pain-free rates from 45.6% to 78.9%. 3

Optimal Dosing Strategy

• Rizatriptan dosing: The standard dose is 10 mg at migraine onset, which provides greater efficacy than 5 mg (up to 77% pain relief at 2 hours vs. 37% with placebo). 4

• Meloxicam dosing: Standard NSAID dosing applies—ensure adequate dosing without exceeding maximum daily limits. 1

• Timing is critical: Counsel patients to begin treatment as soon as possible after migraine onset, ideally while pain is still mild, to maximize efficacy. 1, 2

• Redosing: If the migraine returns, a second dose of rizatriptan may be administered 2 hours after the first dose, with a maximum of 30 mg in 24 hours. 4

Critical Frequency Limitation to Prevent Medication-Overuse Headache

• Limit all acute migraine medications to no more than 2 days per week (10 days per month) to prevent medication-overuse headache, which can paradoxically increase headache frequency and lead to daily headaches. 1, 2

• The threshold for medication-overuse headache varies by treatment: ≥15 days per month with NSAIDs and ≥10 days per month with triptans. 1

• If the patient requires acute treatment more than twice weekly, initiate preventive therapy immediately rather than allowing increased frequency of acute medication use. 1, 2

Safety Considerations and Contraindications

Rizatriptan Contraindications:

• Cardiovascular disease: Do not use in patients with ischemic heart disease, previous myocardial infarction, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease. 2, 5

• Cerebrovascular disease: Contraindicated in patients with cerebrovascular disease or hemiplegic/basilar migraine. 4

Meloxicam (NSAID) Contraindications:

• Renal impairment: Use with caution in patients with creatinine clearance <30 mL/min. 2

• Gastrointestinal risk: Avoid in patients with active GI bleeding or history of GI bleeding, particularly in elderly patients who have increased risk. 2, 5

• Cardiovascular considerations: Monitor for cardiovascular effects, especially in elderly patients. 5

Special Populations

Elderly Patients:

• NSAIDs remain first-line but require careful monitoring due to age-related risks of gastrointestinal bleeding and renal effects. 5

• Triptans are generally not recommended as first-line in elderly patients due to potential cardiovascular risks, though no robust evidence supports increased risk specifically in older people. 5

• Regular blood pressure monitoring is advised if triptans are used in elderly patients. 5

Pregnancy and Lactation:

• Discuss adverse effects of pharmacologic treatments during pregnancy and lactation with patients of childbearing potential before initiating therapy. 1

When to Escalate Treatment

• If combination therapy fails after 2-3 migraine episodes, consider switching to a different triptan (failure of one does not predict failure of others) or escalating to CGRP antagonists (gepants) or ditans. 1, 2

• For severe nausea or vomiting, consider non-oral triptan formulations (subcutaneous or intranasal) and add an antiemetic. 1, 2

• If episodic migraine occurs frequently or treatment does not provide adequate response, preventive medications are warranted. 1

Common Pitfalls to Avoid

• Do not use opioids or butalbital for acute episodic migraine treatment—these lead to dependency, rebound headaches, and loss of efficacy. 1, 2

• Do not allow patients to increase frequency of acute medication use in response to treatment failure—this creates a vicious cycle of medication-overuse headache. 2

• Do not prescribe rizatriptan to propranolol-treated patients without dose adjustment: In adults taking propranolol, only the 5 mg dose of rizatriptan is recommended, up to a maximum of 3 doses in 24 hours (15 mg total). 4